Cannabix Technologies Inc. (CSE: BLO) has announced the first commercial delivery of its breath-based multi-drug test panel, modelled after the U.S. Department of Transportation's federally mandated urine drug testing program. The panel covers five drug classes — amphetamines/methamphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) — and is designed to detect recent drug use within a 15-minute to 4-hour window following consumption. The milestone extends Cannabix's breath-testing platform beyond cannabis detection and may draw attention from investors tracking workplace safety technology.

Key Points

  • Cannabix Technologies Inc. (CSE: BLO | OTCID: BLOZF | Frankfurt: 8CT)
  • First commercial delivery of a breath-based DOT-like multi-drug test panel covering five federally recognised drug classes
  • Panel validated by Omega Laboratories, Inc. using the Cannabix Breath Collection Unit and Breath Cartridge technologies; detection window of 15 minutes to 4 hours post-consumption
  • Investors may watch for further commercial deployments and adoption across workplace, criminal justice, and safety-sensitive testing programmes

Omega Laboratories Validation Enables Multi-Drug Breath Detection

The first commercial delivery follows validation by Omega Laboratories, Inc. of a laboratory-developed test method utilising Cannabix's Breath Collection Unit and Breath Cartridge technologies. The validated method supports simultaneous detection of multiple drug classes from breath samples, the release states. This validation marks a significant technical step, demonstrating that the Cannabix platform can move beyond cannabinoid detection and support a broader range of substances under a single breath-collection framework with laboratory mass spectrometry confirmation.

Short Detection Window Targets Safety-Sensitive Environments

A core differentiator cited in the announcement is the panel's focus on recent-use detection. Unlike urine or hair testing — which can identify drug exposure over days, weeks, or months — the Cannabix breath-based approach is designed to target a detection window of 15 minutes to 4 hours after consumption. The company states this shorter window is more relevant in safety-sensitive situations, and the system incorporates observed breath collection, chain-of-custody procedures, split-sample capability, and laboratory confirmation to support evidentiary defensibility.

Target Markets Span Workplace, Criminal Justice, and Post-Incident Testing

Cannabix identifies several application areas for the new DOT-like panel, including workplace drug testing programmes, criminal justice and treatment monitoring, post-incident investigations, and reasonable-suspicion testing. The company positions the panel as suitable where scientific rigour and operational practicality are both required. The expansion beyond marijuana detection broadens the addressable market for its existing Breath Collection Unit and Breath Cartridge hardware platform, which is already central to its Marijuana Breath Test product line.